Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lachgar

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 11, 1999
HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processesH Le Buanec, R D'Anna, A Lachgar, et al.
Journal of Human Virology|April 9, 1999
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patientsA Gringeri, E Santagostino, M Muça-Perja, et al.
Journal of Human Virology|April 9, 1999
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccineJ F Zagury, A Sill, W Blattner, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 1998
C-C chemokines, pivotal in protection against HIV type 1 infectionD Zagury, A Lachgar, V Chams, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progressionH Hendel, N Hénon, H Lebuanec, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 1, 1996
Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up reportA Gringeri, E Santagostino, M Cusini, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 11, 1999
HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processesH Le Buanec, R D'Anna, A Lachgar, et al.
Journal of Human Virology|April 9, 1999
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patientsA Gringeri, E Santagostino, M Muça-Perja, et al.
Journal of Human Virology|April 9, 1999
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccineJ F Zagury, A Sill, W Blattner, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 1998
C-C chemokines, pivotal in protection against HIV type 1 infectionD Zagury, A Lachgar, V Chams, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progressionH Hendel, N Hénon, H Lebuanec, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 1, 1996
Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up reportA Gringeri, E Santagostino, M Cusini, et al.
Pageof 4